{"id":"NCT03136328","sponsor":"Montefiore Medical Center","briefTitle":"Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan","officialTitle":"Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-16","primaryCompletion":"2017-03","completion":"2017-03","firstPosted":"2017-05-02","resultsPosted":"2019-01-30","lastUpdate":"2023-05-09"},"enrollment":11,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Neuroendocrine Tumors"],"interventions":[{"type":"DRUG","name":"68Ga-DOTATOC","otherNames":["Diagnostic test"]}],"arms":[{"label":"68Ga-DOTATOC PET/CT","type":"EXPERIMENTAL"}],"summary":"The primary goal of the analysis is to estimate the diagnostic accuracy of Gallium 68 (68Ga) -DOTATOC PET/CT for detecting neuroendocrine tumors (NETs) compared to conventional imaging techniques such as Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT). Participants with histologically and/or clinically confirmed and/or suspected NET will be enrolled.","primaryOutcome":{"measure":"Sensitivity to Correctly Diagnose NET","timeFrame":"During imaging process ( approximately 120 minutes)","effectByArm":[{"arm":"68Ga-DOTATOC PET/CT","deltaMin":75,"sd":null},{"arm":"Conventional Imaging","deltaMin":75,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":10,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":11},"commonTop":[]}}